Investigating how abnormal signaling in brain tumors affects immune response in glioblastoma
Official title: Aberrant activation of epidermal growth factor receptor signaling drives programming of an immunosuppressive brain tumor microenvironment in glioblastoma
Funded at University of California Los Angeles · NIH-10998458 · Data updated 2026-11-12
This study is looking at how a specific protein called EGFR makes it harder for the immune system to fight glioblastoma, a tough type of brain tumor, and it hopes to find new ways to boost the immune response to help patients like you.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project start | August 1, 2024 |
| Project end | July 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $44,670 |
| NIH project number | 1F31CA294887-01 |
| Project ID | NIH-10998458 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with glioblastoma who may benefit from novel immunotherapy approaches.
✕Less likely to help
Patients with other types of brain tumors or those who are not diagnosed with glioblastoma may not receive benefits from this research.
What this research studies
This research focuses on glioblastoma, the most common and aggressive brain tumor, which often resists effective treatments. The study aims to understand how abnormal activation of the epidermal growth factor receptor (EGFR) contributes to an immunosuppressive environment in the brain, hindering the body's ability to fight the tumor. By using advanced models, the researchers will explore whether targeting EGFR can enhance immune responses against glioblastoma. This could lead to new therapeutic strategies that improve outcomes for patients suffering from this challenging condition.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options that enhance the immune system's ability to combat glioblastoma.
How similar studies have gone: Previous research has shown promise in targeting EGFR in other cancers, but this specific approach in glioblastoma is relatively novel and untested.
Where this research is happening
-
University of California Los Angeles
Los Angeles, United States Active
Researchers
- Principal investigator: Pioso, Marissa S — University of California Los Angeles
- Study coordinator: Pioso, Marissa S
Related research
Other NIH-funded projects on the same topics.
-
Small molecules to block Slit2/ROBO in glioblastoma
A study to test small molecule drugs that block Slit2/ROBO signals to help treat glioblastoma in patients.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
Small-molecule and biologic treatments for glioblastoma using targeted brain delivery
A new approach aims to use FPS-ZM1 to shrink brain swelling and support immunotherapy for glioblastoma, potentially helping patients recover after surgery.
-
Targeted therapies for glioblastoma in adults and kids
A large NIH program is exploring new brain cancer therapies, including drugs that reach the brain and work against glioblastoma in both children and adults.
-
6-thio-2'-deoxyguanosine for glioblastoma: a new approach to target tumors before surgery
A trial tests a novel drug given before glioblastoma surgery to see how it behaves in the body and within the tumor, and to learn how it affects cancer cells and the immune environment.
-
CD38-Driven Changes in Brain Tumor Metabolism and Immunity in Glioblastoma
A patient-facing look at how scientists plan to study how glioblastoma grows by changing its metabolism and dampening the immune response, with potential targets to help treatment in the future.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.